CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study

References

• Bast R C, Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
   PubMed Web of Science ®Google Scholar
• Kabawat S E, Bast R C, Jr, Bhan A K, Welch W R, Knapp R C, Colvin R B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983; 2: 275–85
   PubMed Web of Science ®Google Scholar
• Canney P A, Moore M, Wilkinson P M, James R D. Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765–9
   PubMed Web of Science ®Google Scholar
• Dietel M. Antigen detection by the monoclonal antibodies CA 19.9 and CA 125 in normal and tumor tissue and patients sera. J Cancer Res Clin Oncol 1986; 111: 257–65
   PubMed Web of Science ®Google Scholar
• Ciobanu N, Runowiez C D, Wiernik P H, Strauman T, Sheridan C, Bast R C, Jr. CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol 1989; 160: 354–5
   PubMed Web of Science ®Google Scholar
• Jones O W, Surwit E A. Meigs syndrome and elevated CA 125. Obstet Gynecol 1989; 73: 520–1
   PubMed Web of Science ®Google Scholar
• Ruibal A. CA 125, marcador de los tumores epiteliales de ovario. Med Clin (Bare) 1988; 91: 54–7
   PubMedGoogle Scholar
• Bast R C, Jr, Klug T L, St John E, Jenison E, Niloff J M, Lazarus H, Berkowitz R S, Leavitt T, Griffiths C T, Parker L, Zurawski V R, Jr, Knapp R C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
   PubMed Web of Science ®Google Scholar
• Touitou Y, Bogdan A. Etude critique des marqueurs tumoraux recents. Bull Cancer (Paris) 1988; 75: 247–62
   PubMed Web of Science ®Google Scholar
• Talbot R W, Nagorney D M, Pemberton J H, Wieand H S, Ritts R E, Jr. Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA 19–9, and CA 125 tumor-associated antigens in patients with colorectal and pancreatic cancer. Cancer Res 1989; 49: 542–3
   PubMed Web of Science ®Google Scholar
• Patsner B, Mann W J. Use of serum CA-125 in monitoring patients with uterine sarcoma A preliminary report. Cancer 1988; 62: 1355–8
   PubMed Web of Science ®Google Scholar
• Jalanko H, Haglund C, Roberts P J, Kuuscla P. Tumor markers in gastrointestinal cancers. Tumor Marker Antigens, J Holmgrem. Studentlitteratur, Lund 1985; 114–22
   Google Scholar
• Ballesta A M, Molina R, Borras G, Elena M, Casals E, Marin J L, Iglesias J. Balague A Antígeno carbohidrato CA 12.5 como marcador tumoral. Rev Diag Biol 1985; 34: 184–94
   Google Scholar
• Ruibal A, Encabo G, Miralles E M, Murcia C, Capdevila J A, Martinez-Vazquez J M, Setoaín J, Doménech-Torné F M. CA 125 seric levels in human clinical practice. Our experience in 1542 cases. International Meeting on Monoclonal Antibodies in Oncology: Clinical applications, NantesFrance, 1984
   Google Scholar
• Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19–9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987; 28: 323–9
   PubMed Web of Science ®Google Scholar
• Bergmann J F, Bidart J M, George M, Beaugrand M, Levy V G, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59: 213–7
   PubMed Web of Science ®Google Scholar
• Eerdekens M W, Nouwen E J, Pollet D E, Briers T W, De Broe M E. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases. Clin Chem 1985; 31: 687–90
   PubMed Web of Science ®Google Scholar
• Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol 1988; 24: 1083–91
   PubMedGoogle Scholar
• Halila H, Stenman U H, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327–29
   PubMed Web of Science ®Google Scholar
• Du L TH, Mohattanc H, Piette J C, Bogdan A, Auzeby A, Touitou Y, Godcau P. Spécifité du marqueur tumoral CA 125. Etude de 328 observations dc médecine interne. Presse Med 1988; 17: 2287–91
   PubMedGoogle Scholar
• Pittaway D E, Douglas J W. Serum CA 125 in women with cndometriosis and chronic pelvic pain. Fertil Steril 1989; 51: 68–70
   PubMed Web of Science ®Google Scholar
• Eiscrmann J, Collins J L. Enzyme immune assay determination of CA 125 in serum, peritoneal fluid, and follicular fluid from women with minimal endometriosis after ovarian hyperstimulation. Fertil Steril 1989; 51: 344–7
   PubMed Web of Science ®Google Scholar
• Mezger J. Elevated serum CA 125 levels in patients with benign ascites or pleural effussions. Tumor Biol 1988; 9: 47–52
   PubMedGoogle Scholar
• Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M. Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 1986; 292: 30–4
   PubMed Web of Science ®Google Scholar
• Ruihal A, Encabo G, Martinez-Miralles E, Murcia C, Capdevila J A, Salgado A, Martinez-Vazquez J M. CA 125 seric levels in non malignant pathologies. Bull Cancer (Paris) 1984; 71: 145–6
   PubMed Web of Science ®Google Scholar
• Ruibal A, Siurana R. Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascitis and jaundice. Int J Biol Markers 1986; 1: 55–6
   PubMedGoogle Scholar
• Ricolleau G, Chatal J F, Fumoleau P, Kremer M, Douillard J Y, Curtet C. Radioimmunoassay of the CA 125 antigen in ovarian carcinomas: advantages compared with CA 19–9 and CEA. Tumor Biol 1984; 5: 151–9
   PubMedGoogle Scholar
• Bergmann J F, Beaugrand M, Labadie H, Bidart J M, Bohuon C. CA 125 (ovarian tumourassociated antigen) in ascitic liver diseases. Clin Chim Acta 1986; 155: 163–6
   PubMed Web of Science ®Google Scholar
• Jacobs I, Bast R C, Jr. The CA 125 tumorassociated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12
   PubMed Web of Science ®Google Scholar
• Ronay G, Jäger W, Tulusan A H. Immunhistochemischer und serologischer Nachweis des CA-125 bei Patientinnen mit Peritonealtuberkulose und Aszites. Geburtshilfe Frauenheilkd 1989; 49: 61–3
   PubMedGoogle Scholar
• Hunter V J, Weinberg J B, Haney A F, Soper J T, Lavin P, Metsch L, Knapp R C, Bast R C, Jr. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 1990; 36: 161–5
   PubMed Web of Science ®Google Scholar
• Fleuran G J, Nap M, Aalders J G, Trimbos J B, de Bruijn H W. Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patient with ovarian tumors. Cancer 1987; 60: 2437–42
   PubMed Web of Science ®Google Scholar
• Aguilar Reina J, Rey Romero C, Ortega Viñas M, Hernandez Pascual A., Sayago Mota M. Cancer antigen 125 levels in serum can predict the recurrence of ascites in patients with cirrhosis of the liver. Hepatogastroenterology 1990; 37(Suppl. 2)163–5
   PubMedGoogle Scholar
• Kobayashi H, Miyaque W, Yamashita M, Kanayama N, Hayata T, Kawashima Y. The mechanism of the increase in serum CA 125 concentration in patients with endometriosis. Nippon Sanka Fujinka Gakkai Zasshi 1988; 40: 467–72
   PubMedGoogle Scholar
• Kobayashi H. Fundamental and clinical study on source of CA 125 antigen in cul-de-sac fluid and translation into systemic circulation. Nippon Sanka Fujinka Gakkai Zasshi 1989; 41: 390–6
   PubMedGoogle Scholar
• Duan H J, Itoh N, Yamagami O, Katsuyama T, Shigematsu H. Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125. Acta Pathol Jpn 1991; 41: 158–63
   PubMedGoogle Scholar
• Talbot R W, Jacobsen D J, Nagorney D M, Malkasian G D, Ritts R E, Jr. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989; 168: 407–12
   PubMedGoogle Scholar